Abstract:
|
Drug development entails a series of information-gathering trials. Good trial design requires clarity around key uncertainties and tradeoffs, which can be informed by a combination of expert opinion and modeling of available data. We review expert biases that should be avoided, and describe pragmatic elicitation methods in the context of the decision analysis cycle. Examples from past clinical trial design decisions illustrate the methods in practice.
|